• MJHLS Brand Logo

© 2025 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Published on: 

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

Key Takeaways

  • CellCentric’s $120 million Series C funding supports late-stage development of inobrodib, a novel oral p300/CBP inhibitor for multiple myeloma.
  • Inobrodib’s mechanism targets MYC and IRF4 expression, addressing therapy resistance in relapsed or refractory multiple myeloma patients.
  • Planned trials include phase II/III studies and combination therapies with bispecific antibodies, advancing toward potential regulatory approval.

A $120 million Series C funding round was completed by CellCentric, a Cambridge, UK-based clinical-stage biotechnology company, for the advancement of inobrodib, which CellCentric is developing as a potential first-in-class oral treatment for several specific types of cancer, notably multiple myeloma (1).

CellCentric describes inobrodib as a novel, oral p300/CBP inhibitor (1). The p300/CBP coactivator family is comprised of p300—also known as adenovirus early region 1A, or E1A, binding protein p300—and CBP, or CREB-binding protein, in which CREB represents cAMP response element-binding protein, with cAMP standing for cyclic adenosine monophosphate (2,3). Targeting this has a desired end result of lowering the expression of transcription factor MYC and interferon regulatory factor 4 (IRF4), two key drivers of cancer (1,4).

New pathway for multiple myeloma treatment

According to CellCentric, the majority of patients diagnosed with multiple myeloma eventually succumb to the disease, and many are either not eligible for, or become resistant to, available therapies (1). Inobrodib’s oral delivery and mechanism of action provide another option, and a phase IIa dose optimization clinical study is currently ongoing that is combining inobrodib with two oral treatments, pomalidomide and dexamethasone.

Advertisement

The Series C funding will be used to support initiation of a phase II/III study in heavily pretreated patients with multiple myeloma, development activities for a phase III program to start in mid-2026, and initiation of trials to start almost instantaneously, within the second quarter of 2025, combining inobrodib with bispecific antibodies (1).

Major funding partners

Financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital and BrightEdge, the venture capital and impact investment arm of the American Cancer Society.

“We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible,” Will West, CellCentric CEO, said in a company press release issued May 19, 2025 (1). “This is a significant raise in a challenging market. Today’s announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team.”

“CellCentric has developed an innovative and impactful therapy for multiple myeloma with inobrodib, a first-in-class oral p300/CBP inhibitor,” Jasper Bos, general partner at Forbion, said in the release; Bos is joining the CellCentric board (1). “This novel agent has demonstrated promising efficacy and a manageable safety profile in early clinical trials. We are enthusiastic about supporting CellCentric as it advances inobrodib into registration studies, aiming to transform multiple myeloma treatment across various stages of the disease.”

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has moved forward several potential treatments for multiple myeloma since late 2024. CHMP’s September 2024 meeting resulted in a recommendation for approval for a generic form of pomalidomide made by Teva, while conditional marketing authorization was granted for a trabectedin generic, from Accord Healthcare, for treatment of relapsed or refractory multiple myeloma at CHMP’s February 2025 summit (6,7).

References

1. CellCentric. CellCentric Secures $120 Million Investment to Advance Inobrodib for Treating Multiple Myeloma. Press Release. May 19, 2025.
2. National Cancer Institute. Definition of p300/CBP Bromodomain Inhibitor CCS1477. Cancer.gov (accessed May 20, 2025).
3. ScienceDirect. EP300—An Overview. ScienceDirect.com (accessed May 20, 2025).
4. Bae, S.; Park, P. S. U.; Lee, Y.; et al. MYC-Mediated Early Glycolysis Negatively Regulates Proinflammatory Responses by Controlling IRF4 in Inflammatory Macrophages. Cell Rep. 2021, 35 (11) 109264. DOI: 10.1016/j.celrep.2021.109264
5. EMA. Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024. Press Release. Sept. 20, 2024.
6. EMA. Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025. Press Release. Feb. 28, 2025.